Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Frankfurt - Delayed Quote EUR

Hisamitsu Pharmaceutical Co., Inc. (HPX.F)

Compare
24.80
+0.20
+(0.81%)
At close: April 4 at 8:13:01 AM GMT+2
Loading Chart for HPX.F
  • Previous Close 24.60
  • Open 24.80
  • Bid 24.00 x 40000
  • Ask 26.20 x 40000
  • Day's Range 24.80 - 24.80
  • 52 Week Range 21.00 - 28.80
  • Volume 75
  • Avg. Volume 1
  • Market Cap (intraday) 1.818B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 19.08
  • EPS (TTM) 1.30
  • Earnings Date Apr 10, 2025
  • Forward Dividend & Yield 0.54 (2.16%)
  • Ex-Dividend Date Feb 27, 2025
  • 1y Target Est --

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United States of America, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.

www.global.hisamitsu

2,759

Full Time Employees

February 29

Fiscal Year Ends

Recent News: HPX.F

View More

Performance Overview: HPX.F

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

HPX.F
9.71%
Nikkei 225 (^N225)
15.33%

1-Year Return

HPX.F
261.64%
Nikkei 225 (^N225)
15.07%

3-Year Return

HPX.F
506.06%
Nikkei 225 (^N225)
21.79%

5-Year Return

HPX.F
225,749.02%
Nikkei 225 (^N225)
89.56%

Compare To: HPX.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HPX.F

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    1.82B

  • Enterprise Value

    1.11B

  • Trailing P/E

    19.10

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.99

  • Price/Book (mrq)

    1.12

  • Enterprise Value/Revenue

    1.20

  • Enterprise Value/EBITDA

    8.19

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    150.13B

  • Net Income Avi to Common (ttm)

    15.54B

  • Diluted EPS (ttm)

    1.30

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    116.64B

  • Total Debt/Equity (mrq)

    1.12%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: HPX.F

View More

Company Insights: HPX.F

Research Reports: HPX.F

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.